Biotechnology

• 10/26/2024

  Navigating the Challenges of Acurx Pharmaceuticals: A Balanced Perspective

• 10/25/2024

  “Cabaletta Bio: Unlocking the Power of CAR-T Compounds for Breakthrough Treatments”

• 10/25/2024

  “Revolutionizing Gene Editing: Editas Medicine’s Strategic Update”

• 10/25/2024

  “Revolutionizing Disease Treatment: The $10 Billion Gene Editing Opportunity”

• 10/24/2024

  Revolutionizing B-Cell Therapeutics: The Obexelimab Breakthrough

• 10/24/2024

  Y-mAbs Therapeutics: A Biotech Powerhouse with Breakthrough Cancer Treatments

• 10/23/2024

  Revolutionizing Disease Treatment: uniQure’s Breakthrough Gene Therapies

• 10/23/2024

  “BriaCell Therapeutics: Revolutionizing Cancer Treatment with Bria-IMT”

• 10/23/2024

  Revolutionizing Healthcare Investing: A Quantitative Approach to Precision Medicine

• 10/22/2024

  Sartorius Stedim Biotech Q3 2024 Earnings Call: Full Transcript